Signal Report · US
BMY HOLD
Composite decision report grounded in 1-XH strategy signals and multi-agent debate, generated by DeepSeek at 2026-06-26 08:47.
🎯 Final Decision
Action
HOLD
Weight
0%
Confidence
30%
Variant
xiaohan_gogo_v2
Reasons
- Bull case relies on a weak 0.70 buy score and a composite z-score that didn't earn a production basket slot.
- Bear case is backward-looking and ignores mean-reversion potential, but the EMA structure is still bearish.
- Both sides have surviving counters, making the risk/reward too uncertain for a decisive trade.
- Regime tilt is neutral; no strong catalyst to override the mixed signals.
Bull Case (Analyst)
- The technical signal is a clear "buy" (score 0.70) with a multi-timeframe bottom pattern (1h through daily), indicating strong momentum reversal potential from the $55.40 close. - The cross-sectional factor view ranks BMY 17th out of 251 stocks (top 6.8%) with a composite z-score of +0.64, placing it in the upper echelon of the BULL catalog despite not making the production basket. - The top lifter, xh_gogo_score (+3.00 z), directly corroborates the technical signal — this factor is the strongest contributor to BMY's long case, aligning with the gogo_detail's bottom detection across all timeframes. - Volume_momentum_60d (+1.03 z) and downside_vol_60d (+0.77 z) suggest recent accumulation and a volatility structure that often precedes mean reversion rallies in pharma names.
Bear Case (Analyst)
- The cross-sectional factor view's top draggers are all risk-adjusted performance metrics: sharpe_60d (-0.84 z), close_to_high_60d (-0.82 z), and beta_60d (-0.62 z) — indicating BMY has been a chronic underperformer with poor reward-to-risk and is trading far from its 60-day high. - BMY is not in the production basket, meaning the quant model's top-down selection process did not find it compelling enough to trade despite the +0.64 composite z — a cautionary signal that other names in the same regime offer better risk/reward. - The sole news item is about AbbVie acquiring Apogee, not BMY — this is a sector-adjacent M&A event that could divert investor attention and capital away from BMY toward the acquisition target or AbbVie. - The technical signal's EMA structure is bearish: the slow EMA ($55.89) sits above the fast EMA ($55.20), and the close ($55.40) is below the slow EMA, meaning the "buy" signal is a bottom-fishing call against a still-negative trend alignment.
Devil's Advocate
COUNTER TO BULL: - A 0.70 buy score is weak — barely above threshold, not a conviction signal. Multi-timeframe bottom patterns in pharma often form dead-cat bounces, not reversals. - Composite z-score of +0.64 is mediocre; top 6.8% sounds impressive but the BULL catalog is a filtered subset, not the full universe. BMY didn't even make the production basket — the model explicitly passed on it. - xh_gogo_score (+3.00 z) is a momentum factor that can spike on short-covering or low-liquidity prints. It does not "corroborate" a bottom — it may simply reflect the same transient technical noise. - Volume_momentum_60d and downside_vol_60d are lagging indicators. Accumulation after a downtrend is often distribution in disguise, especially in pharma where institutional churn is high. COUNTER TO BEAR: - Risk-adjusted metrics like sharpe_60d and close_to_high_60d are backward-looking and penalize stocks precisely when they are most washed out — the classic value trap argument. Underperformance is the precondition for mean reversion, not a reason to avoid it. - Not being in the production basket is a weak signal — the basket is optimized for capacity and turnover constraints, not pure alpha. Many high-z names are excluded for diversification or liquidity reasons. - The AbbVie/Apogee news is sector-adjacent M&A that could actually lift BMY by repricing the entire pharma space upward — capital rotation into laggards is a common post-deal pattern. - The EMA structure is bearish only if you ignore that the fast EMA is rising toward the slow EMA. A close below the slow EMA is typical for a bottom pattern — the "buy" signal explicitly calls for a trend reversal, not confirmation.
Technical Signal (1-XH)
action
buy
score
0.70
variant
xiaohan_gogo_v2
timestamp
2026-06-25 15:30:00
close
55.4
ema_low_fast
55.2
ema_high_slow
55.89
gogo_score
0.7
gogo_detail
1h_bottom,2h_bottom,3h_bottom,4h_bottom,daily_bottom
📈 Backtest Track Record xiaohan_gogo_v2 · signals simulated over available history (~3-month 30-min window, accumulating daily)
Trades
1
Win rate
100%
Avg / trade
+0.1%
Total (compounded)
+0%
best / worst
+0.1% / +0.1%
avg holding
2.2 days
open position
yes — marked-to-market +0.1%
| Entry | Exit | Entry | Exit | Return | Exit reason |
|---|---|---|---|---|---|
| 2026-06-23 | open | 55.37 | 55.40 | +0.1% | open_position_mark_to_market |
News & social (1 items)
-
wsj.comAbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion - WSJThis copy is for your personal, non-commercial use only. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/business/deals/abbvie-to-buy-apo…